Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by Boomskidon Jan 24, 2023 3:55pm
128 Views
Post# 35243234

RE:5 business days until the expiry of the J&J option

RE:5 business days until the expiry of the J&J option
How about this scenario about the J&J impending agreement expiration:
 
Very simple.
 
Let's say that J&J, as the agreement expiration approaches, wants to discuss expanding their agreement with Bioasis. DrDR says to them, "Don't worry about our agreement expiring. We're doing some restructuring here and we can wait until that's done before we need to revisit our agreement. I'll send you a note confirming the extension."
 
So let's say the agreement is extended. And let's say that the restructuring involves DrDR setting up another "merger," or is setting up a sale of Bioasis to a private company. 
 
So DrDR tells the buyer that she has a deal or more that will bring an immediate return on investment for the buyer. She might get a little more out of the buyer for Bioasis shareholders but it will be severely discounted from the value of the deal extension with J&J.
 
And what it does is, it makes the buyer more eager to complete the "merger" or buyout of Bioasis because they'll have an immediate ROI.
 
And that leaves Bioasis shareholders with no deal, a deal that could have been done but was used as a sweetener for the buyout. It also means that Bioasis shareholders no longer own Bioasis.
 
The buyer gets xB3 and a deal that could have saved Bioasis.
 
Who would know? It could be entirely hidden from view, and the motives entirely hidden from J&J. They would not need to be part of the plan.
 
But I'm just reading between the lines.  I know nothing for certain.
 
jd
 
<< Previous
Bullboard Posts
Next >>